Fig. 1From: Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathwayKaplan-Meier estimates of survival rates of R/R AML (acute myeloid leukemia) patients following combination therapy of chidamide and anthracycline-based regimen. a OS. b Progression-free survivalBack to article page